ERBB2 and breast cancer: The DESTINY-Breast07 trial’s preliminary results indicate that trastuzumab deruxtecan, alone or combined with pertuzumab, offers substantial clinical benefits for patients with HER2-positive metastatic BC, demonstrating high response rates and extended PFS.